Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President, Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold currently serves as a director of PreludeDx™ and IMPACT Melanoma. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.

Frank Stokes has served as our Chief Financial Officer since December 2017. From January 2017 to December 2017, Mr. Stokes served as Chief Financial Officer of Hammock Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of women’s health and urology products. From May 2011 to December 2016, Mr. Stokes served as a Managing Director of Leerink Swann (now SVB Leerink). Mr. Stokes also held positions as a Managing Director at Robert W. Baird & Co. Incorporated and Wachovia Securities, LLC. While at SVB Leerink and Robert W. Baird & Co., Mr. Stokes led life sciences, tools and diagnostics sector investment banking efforts, and managed financings, and mergers and acquisitions transactions. Mr. Stokes serves as a director of Exagen (NASDAQ:XGN), as the Audit Committee chair. Mr. Stokes holds a B.S. degree in business administration and J.D. and MBA degrees from the University of North Carolina at Chapel Hill.

Kristen Oelschlager has served as our Chief Operating Officer since April 2021; previously serving as our Chief Operations Officer from August 2020 to April 2021; Senior Vice President, Clinical Operations, from January 2018 to August 2020; and Vice President, Clinical Operations, from 2013 to 2018. Ms. Oelschlager joined the company as Executive Director of Operations in October 2008 as one of three initial employees, bringing more than 15 years of experience in clinical nursing, clinical operations services and clinical research to her position. She has successfully overseen the growth and development of Castle’s laboratory and clinical research functions from early start-up to full commercial operations.

Toby Juvenal has served as our Chief Commercial Officer since September 2020, previously serving as our Senior Vice President, Sales, from January 2018 to August 2020, and Vice President of Sales from 2013 to 2018. Mr. Juvenal joined the company as Executive Director, Sales and Marketing, in October 2008 as one of its three initial employees. Mr. Juvenal has over 28 years of sales, sales management and managed care experience in the pharmaceutical, biotechnology and diagnostics industries. In his current role, Mr. Juvenal leads Castle’s sales efforts and has been instrumental in the acceleration of sales growth in recent years. Mr. Juvenal has experience in successfully scaling sales organizations and building experienced, highly motivated sales teams to meet the demands of a high-growth environment. Mr. Juvenal has also successfully built and managed teams in corporate training, managed markets and national accounts. Prior to Castle, Mr. Juvenal held management positions at Encysive Pharmaceuticals, deCODE Genetics, Genzyme Pharmaceuticals and Genetics Institute. He began his career at Stuart Pharmaceuticals (now AstraZeneca). Mr. Juvenal obtained a B.S. degree in marketing from the University of Florida.

Sherri Borman has served as Executive Laboratory Director since June 2021, previously serving as Castle’s Laboratory Director from October 2018 – May 2021. Dr. Borman is a multidisciplinary diagnostics leader with significant experience teaching in academic institutions and leading commercial operations in clinical laboratories. With over 20 years of experience, she leads CAP-accredited, New York State-Approved, CLIA-certified high throughput, molecular clinical and research laboratories. She has been successful in scaling laboratory operations and building experienced, highly motivated teams to meet the demands of a high-growth environment. Prior to joining Castle, Dr. Borman served as Laboratory Director in two other clinical diagnostic laboratories, as well as Vice President of Laboratory Operations. She has contributed to the development and validation of several new laboratory developed tests (LDT) in cancers over the course of her career and has co-authored multiple scientific publications. Dr. Borman holds a B.S. in nutritional sciences, with a minor in chemistry, and a Ph.D. in physiological sciences, with a minor in cell biology, anatomy and toxicology, from the University of Arizona. She also completed a NIH Post-Doctoral Fellowship at Oregon Health & Science University. Dr. Borman is board certified, through the American Board of Bioanalysis, as a high-complexity clinical laboratory director and clinical consultant, and as a New York state certified laboratory director with several state licenses.

John Abbott joined Castle in July 2014 and served as Vice President, Controller until July 2021. Since July 2021, he has served as Vice President, Finance, maintaining his controller duties, as well as other finance duties. Mr. Abbott has more than 25 years of finance and accounting experience and has served as a Controller for businesses in the diagnostics, biotechnology, manufacturing and software industries. Throughout his career, Mr. Abbott has focused on leveraging the knowledge and proficiencies of the finance function to support the strategic and operational execution needs of his business partners. Mr. Abbott obtained a B.A. degree in economics from Texas A&M University and a Master of Accounting degree from the University of Texas.

Rebecca Critchley-Thorne, Ph.D., serves as Vice President, Research & Development at Castle Biosciences. Dr. Critchley-Thorne joined Castle in December 2021 as Vice President, R&D, Spatialomics and GI, as part of the acquisition of Cernostics, Inc., where she was the Co-Founder and Chief Scientific Officer. She led the development of the TissueCypher computational pathology platform as well as the TissueCypher Barrett’s Esophagus test and the clinical studies supporting its use. She now oversees research and development for Castle’s tests and pipeline activities. Dr. Critchley-Thorne completed training as a postdoctoral fellow at Stanford University where she focused on highly multiplexed analysis of biomarkers to understand mechanisms of immune dysfunction in various cancer types. She earned a Ph.D. in experimental cancer therapeutics at Imperial College and Cancer Research UK in London, England, and a B.S. Hons degree in Pharmacology from the University of Sheffield in England. Dr. Critchley-Thorne is the author of many medical and scientific publications, principal investigator on NIH-funded research studies and an inventor on several of Castle Biosciences’ patents.

Jay Braxton, Pharm.D., has served as Vice President, Marketing and Brand Manager, Uveal Melanoma (UM), since September 2024. Dr. Braxton joined Castle in 2012 as a Regional Business Director managing the sales team and was promoted to Senior Regional Business Director in 2019. During his tenure in sales, he received two consecutive Circle of Excellence awards in 2018 and 2019, which is the company’s top sales and sales management award. At the end of 2019, Dr. Braxton accepted the role of Executive Director, Medical Affairs, prior to being promoted to Vice President of Medical Affairs in July 2021. Dr. Braxton has over 19 years in sales in the pharmaceutical, biotechnology and diagnostics industries, and over 14 years in sales management. In his current role, Dr. Braxton leads marketing for Castle’s gastroenterology (GI), uveal melanoma, mental health and new product areas.

Hillary Caruso has served as our Vice President, Strategic Operations since June 2022. Dr. Caruso joined Castle in 2019 as a senior scientist and was promoted to Director, Program Management, later that year. In that role, Dr. Caruso built Castle’s Program Management department from ground zero, leading the initial development and implementation of the function, which works cross-functionally to help the Company achieve its numerous strategic objectives. For the 12 years prior, Dr. Caruso served as a research scientist at MD Anderson Cancer Center, ultimately leading a team of scientific researchers in the department of neurosurgery focused on development of multi-pronged immunotherapy for brain tumors through genetic modification of T cells. Dr. Caruso holds a B.S. degree in biology from Texas Christian University and a Ph.D. in biomedical sciences, with a specialization in immunology, from the University of Texas Health Science Center in Houston.

John Cheneval has served as our Executive Director, Business Development, since January 2021, leading Castle’s business development opportunities and pharma engagement activities. He has over 31 years of sales, sales management, marketing, corporate accounts and business development experience in the diagnostics and pharmaceutical sectors, as well as in the licensing of diagnostic assays and intellectual property related to novel genomic tests. Prior to joining Castle, Mr. Cheneval served as Vice President of Pharma Partnerships at HTG Molecular, leading a team of business development professionals. He also spent over 19 years at Ortho-Clinical Diagnostics, a Johnson & Johnson company, and four years at Novartis Molecular Diagnostics. Mr. Cheneval holds a B.S degree in medical technology from the Louisiana State University School of Allied Health.

Kevin Doman has served as our Vice President, Sales, since June 2022. Mr. Doman joined Castle in November 2013 as an Area Manager based in Philadelphia and was promoted to Regional Business Director in May 2015, to Senior Regional Business Director in July 2019 and then to National Sales Director in July 2021. He is responsible for the overall performance of Castle’s sales organization, the profitable achievement of the company’s sales goals and for aligning sales objectives with Castle’s business strategy. Mr. Doman has a proven track record of building and motivating experienced and results-driven sales teams to consistently grow market share and exceed revenue expectations. Prior to joining Castle, Kevin Doman held positions at DUSA Pharmaceuticals and JSJ Pharmaceuticals. Mr. Doman holds a B.S. degree in marketing from St. Joseph’s University.

Dr. Matthew Goldberg has served as our Senior Vice President, Medical, since May 2023. Dr. Goldberg joined Castle in August 2020 as our Medical Director. Prior to joining Castle, Dr. Goldberg was an Assistant Professor in Dermatology and Pathology at the Icahn School of Medicine at Mount Sinai in New York and retains his affiliation as an Assistant Clinical Professor of Dermatology. Before joining the Mount Sinai Dermatology faculty, Dr. Goldberg directed Dermatopathology education for the MedStar Georgetown/Washington Hospital Center dermatology residency program. Dr. Goldberg has a background in translational melanoma research and received the Dermatology Foundation Dermatopathology Research Career Development Award for his research in the field of melanoma epigenetics. Dr. Goldberg graduated summa cum laude from Princeton University and received his medical degree from the Icahn School of Medicine at Mount Sinai, where he graduated with distinction in research. Dr. Goldberg completed his dermatology residency at the University of California, San Francisco, and completed a dermatopathology fellowship at the University of Texas Southwestern. Dr. Goldberg is board certified in dermatology and dermatopathology.

Keli Greenberg has served as our Vice President, Human Resources, since April 2022. Ms. Greenberg joined Castle in July 2020 as our Executive Director, Human Resources. She has over 25 years of leadership experience in a human resources capacity, previously working in hospitality. Ms. Greenberg has also held National Training Director and Executive Human Resources roles. She is a versatile leader and change agent with an outstanding track record of building high-performing cultures that drive revenue performance, service excellence and top-down alignment. Under her leadership, her last company was a two-time winner of the Top 20 Best Places to Work and earned Healthiest Employer recognition. She also played a central role in attainment of the prestigious AAA Four Diamond status at a resort in Scottsdale. Ms. Greenberg has served as an officer on multiple HR Practitioner Association Boards and holds a B.S. degree in hospitality management from Northern Arizona University.

Alice Izzo has served as our Senior Vice President, Marketing, since April 2022. Ms. Izzo joined Castle in September 2013 as our Executive Director, Marketing, and was promoted to Vice President, Marketing, in March 2018. Prior to joining Castle, Ms. Izzo held various leadership positions at Amylin Pharmaceuticals, including Vice President of Corporate Affairs from 2010 until the company’s purchase in 2012. She previously served as Executive Director, Investor Relations, and held marketing, clinical development and project management roles at the company. Ms. Izzo has previously served in operational roles in medical communication companies, including Vice President of Operations at a successful start-up. Ms. Izzo attended Duquesne University where she obtained a B.S. degree in pharmacy before receiving her MBA in marketing from Saint Joseph’s University.

Clare Johnson has served as our Vice President, Clinical Research, since July 2021, previously serving as Executive Director, Clinical Research, since 2018. Ms. Johnson joined Castle in September 2012 as a Project Manager, Research & Development, bringing with her more than 20 years of clinical nursing and clinical research experience. During her time with Castle, she has overseen the growth of the clinical research department in Phoenix. Prior to joining Castle, Ms. Johnson was the Director of Clinical Research for a large multi-specialty practice and was responsible for complete oversight of two separate locations. She has also held roles as a Product Manager and Territory Manager at Amoena Australia.

Michael Maltby has served as our Executive Director, Managed Care, since December 2018. He has over 25 years of experience in the pharmaceutical, diagnostics and healthcare industries, previously serving as Senior Director of Managed Care at MDxHealth Inc. from May 2015 to November 2018, and Director of Managed Care at CardioDx from February 2014 to May 2015. He has also held various positions at Pacific Edge Diagnostics USA Ltd., Sequenom Center for Molecular Medicine, Prometheus Therapeutics & Diagnostics and Automata. Mr. Maltby has supported teams in collaboration across the sales, medical affairs and reimbursement functions to drive improvements in marketed and pipeline products. Mr. Maltby received a B.S. degree in agribusiness from Delaware Valley College of Science and Agriculture in Pennsylvania.

Noreen Manning has served as our Vice President, Reimbursement, since April 2022. Ms. Manning joined Castle in May 2014 as our Director, Reimbursement, bringing more than 15 years of experience in medical billing and project management, and was promoted to Executive Director, Reimbursement, in April 2018. In her current position, Ms. Manning oversees billing operations, and payer policy and contract implementation. She has successfully grown this function at Castle to meet increased needs for payer engagement and communication. Prior to Castle, Ms. Manning was the Associate Director of Reimbursement at Indi (Integrated Diagnostics Inc.) and an Account Executive at Quadax Inc. Ms. Manning specializes in the design, implementation and management of reimbursement programs for molecular diagnostic start-up laboratories.

Bio coming soon.

Trisha Poteet has served as our Vice President, Clinical Services, since July 2021. She has over 10 years of experience in driving the growth of the pre-analytic and post-analytic functions of Castle’s laboratory, including strategy development and operational optimization. Since joining the Company in August 2011, Ms. Poteet has served in various capacities within Castle’s operations and clinical services, including Administrative Coordinator; Senior Manager, Clinical Operations; Director, Clinical Services; and most recently, Executive Director, Clinical Services, before being promoted into her current role. Ms. Poteet holds a B.A. degree in business administration from Point Loma Nazarene University and has completed additional executive leadership coursework through AZ Growth Advisors.

Camilla Zuckero has served as our Vice President, Investor Relations & Corporate Affairs, since January 2022. Ms. Zuckero joined Castle in October 2019 as our Executive Director, Investor Relations & Corporate Communications. In her current role, Ms. Zuckero leads the development and execution of Castle’s investor relations and corporate affairs strategy, including the company’s environmental, social and governance (ESG), corporate communications, public relations and patient advocacy programs. Before joining Castle, Ms. Zuckero was responsible for the investor relations and external communications functions at Sysco Corporation, the world’s largest foodservice distributor. Prior to Sysco, she led investor relations and communications for Opexa Therapeutics, a publicly traded biotechnology company developing novel T-cell therapies for the treatment of autoimmune disorders. Ms. Zuckero is a member of Women in Bio, International Association of Business Communicators, Latin Women’s Initiative and the National Investor Relations Institute, and holds a M.S. degree in marketing and communication.